Lenvatinib, sintilimab combined interventional treatment <i>vs</i> bevacizumab, sintilimab combined interventional treatment for intermediate-advanced unresectable hepatocellular carcinoma
In intermediate-to-advanced HCC, the BeSiIT and LeSiIT groups exhibited acceptable toxicities and comparable PFS, OS, and ORR.
Authors
- Xindi Tian
- Liyu Sun
- Mengran Lang
- Kangwei Zhu (ORCID: https://orcid.org/0009-0006-9856-0656)
- Tianqiang Song (ORCID: https://orcid.org/0000-0001-5979-5213)
- Shaohua Ren (ORCID: https://orcid.org/0000-0002-4400-9045)
- Ruyu Han (ORCID: https://orcid.org/0000-0002-3565-1116)
- Yayue Liu (ORCID: https://orcid.org/0000-0002-4984-8497)
- Leijuan Gan (ORCID: https://orcid.org/0000-0001-9747-6053)
- Lu Chen (ORCID: https://orcid.org/0000-0002-5775-6947)
- Dongming Liu (ORCID: https://orcid.org/0000-0003-1317-1610)
- Guangtao Li (ORCID: https://orcid.org/0000-0003-4719-1564)
Institutions
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
Publication Details
- Journal
- World Journal of Gastroenterology
- Published
- 2024-10-31
- DOI
- https://doi.org/10.3748/wjg.v30.i43.4620
- Citations
- 5
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 1.85
Funders
- Soochow University